Selenium Nanoparticles as a Co-adjuvant with Autolysin Recombinant Protein in the Development of a Vaccine Candidate Against Methicillin-Resistant Staphylococcus Aureus

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Microbiology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2 Associate Professor, Department of Microbiology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

3 Associate Professor, Biotechnology Research Center, Tehran University of Medical Sciences, Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran

4 Professor, Department of Toxicology and Pharmacology, Faculty of Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

Abstract

Background: Methicillin-resistant Staphylococcus aureus (MRSA) causes various infections in susceptible individuals who are resistant to antibiotics, resulting in high morbidity and mortality rates. This study aimed to investigate the adjuvant effect of selenium Nanoparticles (SeNPs) for the purpose of developing an effective vaccine to prevent and reduce the complications of MRSA.
Methods: Autolysin recombinant protein, expressed by IPGD and purified by Ni-NTA chromatography was used to develop the vaccine. Together with alum adjuvant, SeNPs produced in two synthetic and biogenic forms were used as a co-adjuvant to increase the vaccine’s efficacy. Four groups of BALB/c mice were subcutaneously injected with three doses of different vaccine combinations. In order to evaluate humoral immunity, the ELISA test was used to measure total IgG, IgG1, and IgG2a levels. The 30-day survival rate of experimental mice was recorded after they were exposed to a bacterial challenge test of MRSA (1.5 ×108 CFU).
Findings: In both groups receiving autolysin recombinant protein with synthetic SeNPs and with biogenic SeNPs, total IgG were higher than the control group. Compared to the control group, IgG1 and IgG2a increased more in the two previously mentioned groups. After the bacterial challenge test, the survival rate of vaccinated mice was higher than that of the control group.
Conclusion: The results showed that, as a co-adjuvant, synthetic and biogenic SeNPs in combination with autolysin recombinant protein could improve the humoral immune system against MRSA.

Keywords

References

  1. Watkins RR, Holubar M, David MZ. Antimicrobial resistance in methicillin-resistant Staphylococcus aureus to newer antimicrobial agents. Antimicrob Agents Chemother 2019; 63(12): e01216-19.
  2. Algammal AM, Hetta HF, Elkelish A, Alkhalifah DHH, Hozzein WN, El-Saber Batiha G, et al. Methicillin-Resistant Staphylococcus aureus (MRSA): one health perspective approach to the bacterium epidemiology, virulence factors, antibiotic-resistance, and zoonotic impact. Infect Drug Resist 2020; 13: 3255-65.
  3. Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J Adv Res 2020; 21:
    169-76.
  4. Parker D. A live vaccine to Staphylococcus aureus infection. Virulence 2018; 9(1): 700-702.
  5. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A 2014; 111(34): 12288-93.
  6. Kalali Y, Haghighat S, Mahdavi M. Passive immunotherapy with specific IgG fraction against autolysin: analogous protectivity in the MRSA infection with antibiotic therapy. Immunol Lett 2019; 212: 125-31.
  7. Houston P, Rowe SE, Pozzi C, Waters EM, O'Gara JP. Essential role for the major autolysin in the fibronectin-binding protein-mediated Staphylococcus aureus biofilm phenotype. Infect Immun 2011; 79(3): 1153-65.
  8. Pasztor L, Ziebandt AK, Nega M, Schlag M, Haase S, Franz-Wachtel M, et al. Staphylococcal major autolysin (Atl) is involved in excretion of cytoplasmic proteins. J Biol Chem 2010; 285(47): 36794-803.
  9. Haghighat S, Siadat SD, Sorkhabadi SMR, Sepahi AA, Mahdavi M. Cloning, expression and purification of autolysin from methicillin-resistant Staphylococcus aureus: potency and challenge study in Balb/c mice. Mol Immunol 2017; 82: 10-8.
  10. Barnowski C, Kadzioch N, Damm D, Yan H, Temchura V. Advantages and limitations of integrated flagellin adjuvants for HIV-based nanoparticle B-cell vaccines. Pharmaceutics 2019; 11(5): 204.
  11. Vijayan V, Mohapatra A, Uthaman S, Park I-K. Recent advances in nanovaccines using biomimetic immunomodulatory materials. Pharmaceutics. 2019; 11(10): 534-61.
  12. Marques Neto LM, Kipnis A, Junqueira-Kipnis AP. Role of metallic nanoparticles in vaccinology: implications for infectious disease vaccine development. Front Immunol 2017; 8: 239-49.
  13. Vanamala K, Tatiparti K, Bhise K, Sau S, Scheetz MH, Rybak MJ, et al. Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance. Drug Discov Today 2021; 26(1): 31-43.
  14. Mahdavi M, Mavandadnejad F, Yazdi MH, Faghfuri E, Hashemi H, Homayouni-Oreh S, et al. Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model. J Infect Public Health 2017; 10(1): 102-9.
  15. Shakibaie M, Shahverdi AR, Faramarzi MA, Hassanzadeh GR, Rahimi HR, Sabzevari O. Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharm Biol 2013; 51(1): 58-63.
  16. Yazdi MH, Mahdavi M, Varastehmoradi B, Faramarzi MA, Shahverdi AR. The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study. Biol Trace Elem Res 2012; 149(1): 22-8.
  17. Yazdi MH, Masoudifar M, Varastehmoradi B, Mohammadi E, Kheradmand E, Homayouni S, et al. Effect of oral supplementation of biogenic selenium nanoparticles on white blood cell profile of BALB/c mice and mice exposed to X-ray radiation. Avicenna J Med Biotechnol 2013; 5(3): 158.
  18. Modrzejewska-Sikorska A, Konował E, Klapiszewski Ł, Nowaczyk G, Jurga S, Jesionowski T, et al. Lignosulfonate-stabilized selenium nanoparticles and their deposition on spherical silica. Int J Biol Macromol 2017; 103: 403-8.
  19. Søe NH, Jensen NV, Jensen AL, Koch J, Poulsen SS, Pier GB, et al. Active and passive immunization against Staphylococcus aureus periprosthetic osteomyelitis in rats. In Vivo 2017; 31(1): 45-50.
  20. Bagherzadeh M, Haghighat S, Mahdavi M. Evaluation of humoral and cellular immunity of recombinant autolysin protein Staphylococcus aureus in mouse model. Medical Science 2021; 31(2): 146-55.
  21. Kye YC, Park SM, Shim BS, Firdous J, Kim G, Kim HW, et al. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection. Acta Biomater 2019; 90: 362-72.
  22. Han HW, Patel KD, Kwak JH, Jun SK, Jang TS, Lee -H, et al. Selenium nanoparticles as candidates for antibacterial substitutes and supplements against multidrug-resistant bacteria. Biomolecules 2021; 11(7): 1028.
  23. Raahati Z, Bakhshi B, Najar-Peerayeh S. Selenium nanoparticles induce potent protective immune responses against vibrio cholerae WC vaccine in a mouse model. Journal of Immunology Research 2020; 2020: 1-12.
  24. Eid SY, El-Zaher HM, Emara SS, Farid OA-H, Michael MI. Nano selenium treatment effects on thyroid hormones, immunity and antioxidant status in rabbits. World Rabbit Science 2019; 27(2): 93-100.
  25. Mohammadi Y. Evaluation of the immunogenicity and efficacy of a chimeric OMP25–OMP31 antigen in BALB/c mice. Vet Med Sci 2021; 7(5): 2008-14.
  26. Paydarnia N, Mansoori B, Esmaeili D, Kazemi T, Aghapour M, Hajiasgharzadeh K, et al. Helicobacter pylori recombinant CagA regulates Th1/Th2 balance in a BALB/c murine model. Adv Pharm Bull 2020; 10(2): 264-70.
  27. Mavandadnejad F, Yazdi MH, Hassanzadeh SM, Mahdavi M, Faramarzi MA, Pazoki-Toroudi H, et al. Biosynthesis of SeNPs by Mycobacterium bovis and their enhancing effect on the immune response against HBs antigens: an in vivo study. IET Nanobiotechnology 2018; 12(1): 57-63.
  28. Dryla A, Prustomersky S, Gelbmann D, Hanner M, Bettinger E, Kocsis B, et al. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 2005; 12(3): 387-98.
  29. Dos Santos D, Muniz I, Queiroz A, Pereira I, Souza M, Lima L, et al. Individual variation is the key to the development of a vaccine against Staphylococcus aureus: a comparative study between mice lineages. Braz J Med Biol Res 2018; 51(5): 6773-85.
  30. Varshney AK, Wang X, Aguilar JL, Scharff MD, Fries BC. Isotype switching increases efficacy of antibody protection against staphylococcal enterotoxin B-induced lethal shock and Staphylococcus aureus sepsis in mice. mBio 2014; 5(3): e01007-14.
Journal of Isfahan Medical School
Volume 40, Issue 678
2nd Week, September
September and October 2022
Pages 481-489

Files

History

  • Receive Date: 29 August 2022
  • Accept Date: 29 August 2022

Share

How to cite

Statistics